Skip to main content

Table 1 Baseline characteristics

From: Quantiferon Gold-in-tube assay for TB screening in HIV infected children: influence of quantitative values

Characteristics

QFT + (n = 15)

QFT- (n = 65)

P

Mean age

13.8(+/−3.5)

12.1+/−4.5

0.16

Age < 5

0

6(9%)

0.22

Females

5(33.3%)

38(57.5%)

0.09

Mean BMI

20.6+/−3.6

20.2+/−4.6

0.71

Born in TB endemic region

10(66.7%)

46(69.7%)

0.82

Mother born in TB endemic region

14(93.3%)

56(84.9%)

0.39

BCG vaccinated

6(40%)

20(30.3%)

0.47

Mean CD4%

31.4+/−11.3

32.1+/−9.3

0.79

CD4 > 25%

10(66.7%)

53(80.3%)

0.51

CD4 15-25%

4(26.7%)

10(15.2%)

CD4 < 15%

1(6.7%)

3(4.6%)

Mean CD4 count

744+/−331.5

846.7+/−483.8

0.44

Median CD4 count (IQR)

769(481–1043)

731(525–1012)

0.88

Viral load log10 copies/ml

3.6+/−1.3

3.5+/−0.86

0.87

Undetectable viral load

10(66.7%)

39(59.1%)

0.59

No symptoms*

5(33.3%)

18(27.3%)

0.91

Mild symptoms*

5(33.3%0

23(34.8%)

Moderate symptoms*

4(26.7%)

17(25.8%)

Severe symptoms*

1(6.7%)

8(12.1%)

Proportion on ARV

13(86.7%)

55(83.3%)

0.75

Median duration of ARV in years (IQR)

7.33(2.2-10.84)

8.04(1.84-11.8)

0.91

3TC monotherapy

0

4(6.1%)

0.73

Combination ART

13(86.7)

51(77.3%)

0.42

  1. *at initial presentation; BMI – Body Mass Index; CD 4 – Cluster of Differentiation 4; ARV – Anti Retroviral Therapy; 3TC –Lamivudine.